The company’s first diagnostic application for the automated Cell-CT system is the LuCED test, a non-invasive test in development for lung cancer screening.
LuCED and the Cell-CT platform produce detailed 3D images of cells in sputum, which the system automatically analyzes to identify key features, or biosignatures, associated with potential malignancy.
VisionGate chairman and CEO Alan Nelson said they believe the automated Cell-CT platform could revolutionize cell-based diagnostics, both by enabling early disease detection and by providing pathologists with a powerful new tool for a wide range of applications.
VisionGate president Scarlett Spring said achieving full automation of the Cell-CT platform is another on-time milestone in their plans to register for regulatory approval of the LuCED test during 2012.
"It also complements our recently announced strategic partnerships for clinical assessment of the LuCED technology used adjunctively to reduce the high rate of false positive cases that result from x-ray CT lung cancer screening," Spring said.
"We expect these partnerships will provide valuable data to further advance our LuCED regulatory strategy."
